The P(2)-purinoceptor antagonist suramin is a competitive antagonist at vasoactive intestinal peptide receptors in the rat gastric fundus

Br J Pharmacol. 2000 Aug;130(7):1632-8. doi: 10.1038/sj.bjp.0703482.

Abstract

The P(2)-purinoceptor antagonist, suramin, was used to investigate the possible involvement of adenosine 5'-triphosphate (ATP) in the inhibitory non-adrenergic non-cholinergic (NANC) innervation of the rat gastric fundus. ATP (1-30 microM) produced biphasic responses consisting of concentration-dependent relaxations followed by concentration-dependent contractions. Suramin (200 microM) significantly reduced relaxations and abolished contractions to ATP. Under NANC conditions, electrical field stimulation (EFS) induced frequency-dependent relaxations. Suramin (200 microM) and the peptidase alpha-chymotrypsin (1 u ml(-1)) had the same effects on EFS-induced relaxations: their duration was reduced, but their magnitude was unaffected. Cumulative relaxations to vasoactive intestinal peptide (VIP; 0.1-100 nM), and to the VIP analogue pituitary adenylate cyclase activating peptide 1-27 (PACAP; 0.2-100 nM), were almost completely abolished by alpha-chymotrypsin (1 u ml(-1)), and were inhibited by suramin (3-200 microM) in an apparently competitive manner. Schild plot analysis indicated that suramin had pA(2) values of 5.1+/-0.2 (Hill slope=0.9+/-0.2) and 5.6+/-0.1 (Hill slope=1.0+/-0.1), against VIP and PACAP, respectively. Concentration-dependent relaxations to nitric oxide (1-30 microM) and cumulative relaxations to isoprenaline (0.1-300 nM) were not affected by suramin (200 microM). No conclusions can be made regarding the possible involvement of ATP in EFS-induced NANC relaxations. The results suggest that suramin acts as a competitive antagonist at VIP receptors in the rat gastric fundus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / pharmacology
  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Binding, Competitive
  • Drug Interactions
  • Gastric Fundus / drug effects*
  • Gastric Fundus / metabolism
  • In Vitro Techniques
  • Isoproterenol / pharmacology
  • Male
  • Muscle Relaxation / drug effects
  • Neuropeptides / pharmacology
  • Nitric Oxide / pharmacology
  • Nitroprusside / pharmacology
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Purinergic P2 Receptor Antagonists*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Purinergic P2 / metabolism
  • Receptors, Vasoactive Intestinal Peptide / antagonists & inhibitors*
  • Receptors, Vasoactive Intestinal Peptide / metabolism
  • Suramin / pharmacology*
  • Vasoactive Intestinal Peptide / pharmacology
  • Vasodilator Agents / pharmacology

Substances

  • Adcyap1 protein, rat
  • Adrenergic beta-Agonists
  • Neuropeptides
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2
  • Receptors, Vasoactive Intestinal Peptide
  • Vasodilator Agents
  • Nitroprusside
  • Nitric Oxide
  • Vasoactive Intestinal Peptide
  • Suramin
  • Adenosine Triphosphate
  • Isoproterenol